Timeliness of MMR vaccination -: influence on vaccination coverage

被引：48
作者：
Dannetun, E
Tegnell, A
Hermansson, G
Törner, A
Giesecke, J
机构：
[1] Landstinget Ostergotland, Dept Communicable Dis Control, SE-58191 Linkoping, Sweden
[2] Swedish Inst Infect Dis Control, Dept Epidemiol, SE-17182 Solna, Sweden
[3] Landstinget Ostergotland, Cent Unit Child Hlth Care, SE-58191 Linkoping, Sweden
来源：
VACCINE | 2004年 / 22卷 / 31-32期
关键词：
measles; vaccination coverage; pre-school children;
D O I：
10.1016/j.vaccine.2004.04.018
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Over the last seven years, and especially in 2001, a declining coverage for MMR vaccination in 2-year-olds has been noted in Sweden. By recording actual date of vaccination in a cohort of almost 4000 children in a county in central Sweden, we found that parents' decision to postpone vaccination by up to 1.5 years beyond the stipulated age of 18 months accounted for about half the reported drop in 2001. Even if coverage thus improves with time, postponed vaccination adds to the pool of unprotected children in the population. The design of the current national surveillance system overestimates coverage at 2 years and fails to record delayed vaccination. To avoid future outbreaks that can appear around imported cases of measles it is crucial to attain high coverage levels by timely vaccination. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码：4228 / 4232
页数：5
相关论文
共 18 条
  • [1] VACCINATION AND HERD-IMMUNITY TO INFECTIOUS-DISEASES
    ANDERSON, RM
    MAY, RM
    [J]. NATURE, 1985, 318 (6044) : 323 - 329
  • [2] Atkinson William L., 1992, Morbidity and Mortality Weekly Report, V41, P1
  • [3] BART KJ, 1991, JAMA-J AM MED ASSOC, V266, P1547
  • [4] CRONIN M, 2000, EUROSURVEILLANCE WKL, V4
  • [5] De Serres G, 2000, AM J EPIDEMIOL, V151, P1039, DOI 10.1093/oxfordjournals.aje.a010145
  • [6] Passive immunity against measles during the first 8 months of life of infants born to vaccinated mothers or to mothers who sustained measles
    DeSerres, G
    Joly, JR
    Fauvel, M
    Meyer, F
    Masse, B
    Boulianne, N
    [J]. VACCINE, 1997, 15 (6-7) : 620 - 623
  • [7] HAMBURGER H, 2002, EUROSURVEILLANCE WKL, V6
  • [8] Vaccine safety - improving monitoring
    Heijbel, H
    Jefferson, T
    [J]. VACCINE, 2001, 19 (17-19) : 2457 - 2460
  • [9] Hull B P, 1999, Aust Fam Physician, V28, P55
  • [10] Hutchins S S, 2001, MedGenMed, pE5
12